VERA Stock Analysis: Buy, Sell, or Hold?
VERA - Vera Therapeutics, Inc. Class A Common Stock
$43.13
1.63 (3.93%)
▲
5d:
+0.4%
30d:
+28.17%
90d:
-1.33%
BUY
MODERATE Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 04, 2026
19d
Get Alerted When VERA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
4 traders called VERA this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: VERA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: VERA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: VERA is currently trading at $43.13, which is considered extended relative to its 30-day fair value range of $34.12 to $42.58.
Technical Outlook: Technically, VERA is in a downtrend. Immediate support is located at $36.76, while resistance sits at $44.87. The stock is showing strong short-term momentum, up 3.9% recently.
Market Sentiment: VERA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $81.79 (+89.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, VERA is in a downtrend. Immediate support is located at $36.76, while resistance sits at $44.87. The stock is showing strong short-term momentum, up 3.9% recently.
Market Sentiment: VERA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $81.79 (+89.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$34.12 -
$42.58
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
68.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.9%)
- BULLISH: Trading 89.6% below Wall St target ($81.79)
Trading Range Analysis
30-Day Trading Range
$34.12 -
$42.58
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$36.76
Resistance Level
$44.87
Current Trend
Downtrend
Technical data as of
Jul 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-11.18
Wall Street Target
$81.79
(+89.6%)
Share & Embed Analysis
Last updated: July 15, 2026 4:00 AM ET
Data refreshes hourly during market hours. Next update: 5:00 AM
Data refreshes hourly during market hours. Next update: 5:00 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VERA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Marshall Fordyce
SELL
22951 shares
2026-04-14
David Lee Johnson
SELL
2579 shares
2026-02-23
Joseph R Young
SELL
3117 shares
2026-02-23
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$413 | 54 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$822 | 64 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 52 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
